Daniela Saggioro
Overview
Explore the profile of Daniela Saggioro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boldrin E, Curtarello M, Fassan M, Rugge M, Realdon S, Alfieri R, et al.
Front Oncol
. 2020 Sep;
10:1320.
PMID: 32983964
Esophageal cancer (EC) is a highly aggressive tumor, and the current monitoring procedures are partially inadequate to evaluate treatment efficacy. The aim of this study was to investigate whether allelic...
2.
Rumiato E, Boldrin E, Malacrida S, Battaglia G, Sileni V, Ruol A, et al.
Pharmacogenomics
. 2020 Apr;
21(6):393-402.
PMID: 32285752
Clinical features of esophageal cancer (EC) patients have poor prognostic power. Thus, it is paramount to discover biomarkers that can allow a more accurate survival prediction. To detect genetic variants...
3.
Boldrin E, Curtarello M, Dallan M, Alfieri R, Realdon S, Fassan M, et al.
Int J Mol Sci
. 2020 Feb;
21(4).
PMID: 32102481
DNA methylation plays an important role in cancer development. Cancer cells exhibit two types of DNA methylation alteration: site-specific hypermethylation at promoter of oncosuppressor genes and global DNA hypomethylation. This...
4.
Boldrin E, Nardo G, Zulato E, Bonanno L, Polo V, Frega S, et al.
Int J Mol Sci
. 2019 Dec;
21(1).
PMID: 31861832
Liquid biopsy is currently approved for management of epidermal growth factor receptor ()-mutated non-small-cell lung cancer (NSCLC) patients. However, one unanswered question is whether the rate of cell-free DNA (cfDNA)-negative...
5.
Boldrin E, Malacrida S, Rumiato E, Battaglia G, Ruol A, Amadori A, et al.
Front Oncol
. 2019 Mar;
9:85.
PMID: 30847299
Esophageal cancer (EC) is a very aggressive tumor, and no reliable prognostic markers exist especially for resectable advanced neoplasia. The principal aim of this study was to investigate the association...
6.
Rumiato E, Boldrin E, Malacrida S, Realdon S, Fassan M, Morbin T, et al.
Transl Res
. 2017 Oct;
190:16-24.e1.
PMID: 29066320
Barrett's esophagus (BE) is associated with an increased risk of developing esophageal adenocarcinoma. Despite the low absolute risk of neoplastic progression of BE, probability increases with the diagnosis of dysplasia....
7.
Boldrin E, Rumiato E, Fassan M, Balsamo L, Realdon S, Battaglia G, et al.
Transl Res
. 2016 May;
176:127-31.
PMID: 27234667
Barrett's esophagus (BE) is associated with an increased risk of developing esophageal adenocarcinoma. For this reason, endoscopic-based surveillance protocols have been developed. This prevention program is, however, burdensome for the...
8.
Rumiato E, Boldrin E, Amadori A, Saggioro D
Pharmacogenomics
. 2016 May;
17(7):805-20.
PMID: 27181132
Chemoradiotherapy followed by surgery is at present the standard therapeutic approach for esophageal cancer (EC) in patients with resectable tumor. However, response to neoadjuvant therapy is characterized by a strong...
9.
Rumiato E, Boldrin E, Malacrida S, Battaglia G, Bocus P, Castoro C, et al.
Transl Res
. 2016 Jan;
171:29-37.e1.
PMID: 26772957
Platinum-based neoadjuvant therapy is the standard treatment for esophageal cancer (EC). At present, no reliable response markers exist, and patient therapeutic outcome is variable and very often unpredictable. The aim...
10.
Boldrin E, Rumiato E, Fassan M, Cappellesso R, Rugge M, Chiarion-Sileni V, et al.
PLoS One
. 2015 Jan;
10(1):e0117070.
PMID: 25611972
Background: Development of novel therapeutic drugs and regimens for cancer treatment has led to improvements in patient long-term survival. This success has, however, been accompanied by the increased occurrence of...